Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CANDEX | Bayer | N-050233 DISCN | 1982-01-01 | 1 products |
NILSTAT | Chartwell Pharmaceuticals | N-050299 DISCN | 1982-01-01 | 1 products, RLD |
MYCOSTATIN | Delcor Asset | N-050619 DISCN | 1987-04-09 | 1 products |
NILSTAT | Strides Pharma Global | N-050576 DISCN | 1983-12-22 | 1 products, RLD |
NYSERT | Warner Chilcott | N-050478 DISCN | 1982-01-01 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
klayesta | ANDA | 2024-12-19 |
mycostatin | ANDA | 2023-01-05 |
nyamyc | ANDA | 2024-06-18 |
nystatin | ANDA | 2025-01-03 |
nystatin and triamcinolone | ANDA | 2011-05-10 |
nystatin and triamcinolone acetonide | ANDA | 2024-12-19 |
nystatin cream | ANDA | 2023-10-24 |
nystatin topical powder | ANDA | 2023-08-10 |
nystop | ANDA | 2024-12-24 |
triple antibiotic | OTC monograph final | 2017-05-05 |
Drug common name | Nystatin |
INN | nystatin |
Description | Nystatin, sold under the brand name Mycostatin among others, is an antifungal medication. It is used to treat Candida infections of the skin including diaper rash, thrush, esophageal candidiasis, and vaginal yeast infections. It may also be used to prevent candidiasis in those who are at high risk. Nystatin may be used by mouth, in the vagina, or applied to the skin.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2 |
PDB | — |
CAS-ID | 1400-61-9 |
RxCUI | 7597 |
ChEMBL ID | CHEMBL450895 |
ChEBI ID | — |
PubChem CID | 14960 |
DrugBank | DB00646 |
UNII ID | BDF1O1C72E (ChemIDplus, GSRS) |